Laboratoires Pierre Fabre has been granted a patent for an antibody-drug-conjugate for treating breast cancer, lung cancer, and kidney carcinoma. The compound consists of an antibody binding to a target and a drug derived from dolastatin 10 or auristatins. This innovation offers a promising treatment option for cancer patients. GlobalData’s report on Laboratoires Pierre Fabre gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Laboratoires Pierre Fabre SA - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Laboratoires Pierre Fabre, was a key innovation area identified from patents. Laboratoires Pierre Fabre's grant share as of February 2024 was 56%. Grant share is based on the ratio of number of grants to total number of patents.

Antibody-drug-conjugate for treating breast, lung, and kidney cancer

Source: United States Patent and Trademark Office (USPTO). Credit: Laboratoires Pierre Fabre SA

A recently granted patent (Publication Number: US11918656B2) discloses a method for treating various cancers, including breast cancer, lung cancer, and kidney carcinoma. The method involves administering a therapeutically effective amount of a compound with a specific chemical formula. The compound's structure includes different groups such as (C1-C6)alkyl, COOH, COO—(C1-C6)alkyl, thiazolyl, and methyl, among others, which play a crucial role in the treatment process.

Furthermore, the patent claims specify the structure of the compound in detail, including the arrangement of various groups like Het-Alk-, aryl-(C1-C2)alkanediyl, and heterocycle-(C1-C2)alkanediyl. These groups are linked to specific elements within the compound, contributing to its effectiveness in treating the mentioned cancers. Additionally, the patent mentions the use of pharmaceutically acceptable salts, particularly those formed with trifluoroacetic acid, as part of the treatment method. This detailed description of the compound's structure and its interaction with cancer cells provides valuable insights for researchers and healthcare professionals working in the field of oncology.

To know more about GlobalData’s detailed insights on Laboratoires Pierre Fabre, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies